Acrivon Therapeutics’ Mary Miller sells 193 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Acrivon Therapeutics Chief Legal Officer Mary Miller reported a sale of 193 common shares on November 17, 2026, in connection with mandatory tax withholding when restricted stock units vested. The reported $1.45 per-share weighted-average price was for a broker's sale of 4,070 shares for an employee group that included Miller. She directly held 81,009 shares after the transaction. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 193 | $1.45 | $279.85 |
Footnotes (2)
- F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
- F2. The price reported in Column 4 above reflects the weighted average price of 4,070 shares sold by a broker on November 17, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.
Key Figures
Key Terms
restricted stock units financial
weighted average price financial
tax withholding liability financial
pro rata basis financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How were proceeds from ACRV's employee tax-withholding sale allocated?
AI-generated analysis. How Rhea-AI works. Not financial advice.